A Study to Learn About How BAY 3283142 Moves Into, Through, and Out of the Body After a Single Dose in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 17, 2024

Primary Completion Date

February 24, 2025

Study Completion Date

February 24, 2025

Conditions

Chronic Kidney DiseaseHepatic Impairment

Interventions

DRUG

BAY3283142

Single oral dose.

Trial Locations (1)

Orlando Clinical Research Center (OCRC), Orlando